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Abstract
Introduction: Toll-like receptors (TLRs) are a family of receptors that sense pathogen associated patterns such as bacterial
cell wall proteins. Bacterial infections are associated with anti-neutrophil cytoplasmic antibodies (ANCA)-associated
vasculitis (AAV). Here, we assessed the expression of TLRs 2, 4, and 9 by peripheral blood leukocytes from patients with AAV,
and investigated TLR mediated responses ex vivo.
Methods: Expression of TLRs was determined in 38 AAV patients (32 remission, 6 active disease), and 20 healthy controls
(HC). Membrane expression of TLRs 2, 4, and 9, and intracellular expression of TLR9 by B lymphocytes, T lymphocytes, NK
cells, monocytes and granulocytes was assessed using 9-color flowcytometry. Whole blood from 13 patients and 7 HC was
stimulated ex vivo with TLR 2, 4 and 9 ligands and production of cytokines was analyzed.
Results: In patients, we observed increased proportions of TLR expressing NK cells. Furthermore, patient monocytes
expressed higher levels of TLR2 compared to HC, and in a subset of patients an increased proportion of TLR4
+ monocytes
was observed. Monocytes from nasal carriers of Staphylococcus aureus expressed increased levels of intracellular TLR9.
Membrane expression of TLRs by B lymphocytes, T lymphocytes, and granulocytes was comparable between AAV patients
and HC. Patients with active disease did not show differential TLR expression compared to patients in remission. Ex vivo
responses to TLR ligands did not differ significantly between patients and HC.
Conclusions: In AAV, monocytes and NK cells display increased TLR expression. Increased TLR expression by these
leukocytes, probably resulting from increased activation, could play a role in disease (re)activation.
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Introduction
Anti-neutrophil cytoplasmic antibodies (ANCA) associated
vasculitides (AAV) are a group of severe autoimmune disorders,
characterized by necrotizing inflammation of small- to medium-
sized blood vessels. ANCA in AAV are mainly directed against
proteinase 3 (PR3) or myeloperoxidase (MPO) [1,2]. The etiology
of AAV is unknown, although bacterial and viral infections have
been linked to the onset and development of AAV [3,4]. Sixty-
three percent of patients with Wegener’s granulomatosis (WG), a
prototype AAV, are chronic nasal carriers of the bacterium
Staphylococcus aureus, and carriage is associated with an increased
risk for relapses [5,6]. Interestingly, anti-bacterial treatment
reduces the risk for relapses, and can be part of maintenance
therapy [7,8]. Taken together, these findings point towards a link
between infection and autoimmunity, but the underlying mech-
anisms are still unknown.
Toll-like receptors (TLRs) are a family of receptors that sense
pathogen associated molecular patterns (PAMPs) such as bacterial
cell-wall components and DNA [9]. TLRs are expressed by a
variety of cell types, including monocytes, B lymphocytes and
granulocytes, as well as epithelial and endothelial cells [10–13].
TLR ligation results in the production of proinflammatory
cytokines, increased antigen presentation, antibody production,
proliferation, and differentiation [14–16]. Furthermore, TLR
signaling has been suggested to play a role in the regulation of
B-cell tolerance and the development of regulatory B-lymphocytes
[17,18]. TLRs being important during bacterial infection are the
cell-surface receptors TLR2 and TLR4, sensing lipoproteins and
liposaccharides, respectively [19]. Studies in knock-out mice have
shown an important role for TLR4, and a crucial role for TLR2 in
the defense against Gram-positive bacteria such as Staphylococcus
aureus, by regulating proinflammatory cytokine and chemokine
release, and leukocyte recruitment [20,21]. In addition to cell wall
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24315proteins, bacterial DNA is of interest in the context of bacterial
infections. Unmethylated cytosine-phosphate-guanine (CpG) mo-
tifs are prevalent in bacterial DNA, and can be recognized by
TLR9, inducing proinflammatory responses [22]. Recent studies
show that CpG motifs can trigger the production of autoantibodies
in vitro [15,23,24].
A role for TLRs during autoimmune inflammation is likely.
Increased TLR expression has been observed in synovial tissue
and synovial macrophages from patients with rheumatoid arthritis
[25], and involvement of TLR4 has been demonstrated in a mouse
arthritis model [26]. In patients with systemic lupus erythemato-
sus, elevated intracellular TLR9 has been found in B lymphocytes,
possibly reflecting increased B lymphocyte activation in these
patients [27]. Animal studies have shown both aggravating as well
as protective effects of TLR ligands in a lupus model demonstrat-
ing the complexity of the system [28]. In large vessel vasculitis, it
has been shown that different TLR ligands can induce distinct
vasculitis types [29].
Limited data is present about TLRs in AAV. Two studies
investigated whether anti-PR3 antibodies influence the expression
of TLRs on human monocytes, albeit with conflicting results
[30,31]. In mice, it has been shown that lipopolysaccharide (LPS)
aggravates anti-MPO antibody induced injury in a TLR4
dependent manner [32,33], and a recent study showed that
TLR2 and TLR9 ligands can drive the development of anti-MPO
autoimmunity as well [34].
Given the association of AAV with infections it is highly likely
that TLR mediated effector mechanisms play a role in AAV
pathogenesis, but data on leukocyte TLR expression in these
patients is lacking. Therefore, the current study was designed to
characterize the expression of membrane TLR2, TLR4, and
TLR9, and intracellular TLR9 by peripheral blood leukocytes in
AAV patients, in comparison to age-matched healthy individuals.
Using flowcytometry, TLR expression by B lymphocytes, T
lymphocytes, NK cells, monocytes, and granulocytes was deter-
mined. TLR expression was related to serum ANCA titers and
nasal carriage of Staphylococcus aureus. In addition, we studied
whether ANCA priming influences TLR expression, and deter-
mined ex vivo responses to TLR ligands by peripheral blood
leukocytes.
Materials and Methods
Patients
Heparinized blood was collected from 38 AAV patients (mean
age of 60.6613.8 years) and 20 matched healthy individuals (mean
age of 53.6613.7 years). The study was approved by the Medical
Ethics Committee of the University Medical Center Groningen.
Written consent was given by the participants for their blood
samples to be used for research. Table 1 describes patient
characteristics. Six patients had active disease at the time of
inclusion. Disease diagnoses were based on the definitions of the
Chapel Hill Consensus Conference [2]. Twenty-five patients
received no immunosuppressive medication. Thirteen patients
received maintenance therapy at the time of inclusion (prednis-
olone ,10 mg/day, azathioprine or mycophenolate mofetil, but
no cyclophosphamide). Patients were positive for circulating
ANCA at the time of blood sampling.
Flowcytometry
Membrane expression of TLR2, TLR4 and TLR9 by
peripheral blood leukocytes was determined using Fluorescence-
activated cell sorter (FACS). Briefly, 100 ml heparinized blood was
incubated with monoclonal antibodies against membrane markers
CD3 (Biolegend), CD14 (Invitrogen), CD16 (Biolegend), CD19
(BD Biosciences), CD27 (eBioscience), and CD56 (Biolegend), and
toll-like receptors TLR2 (eBioscience, clone TL2.1), TLR4
(eBioscience, clone CD284), and TLR9 (Imgenex, clone IMG-
305). Cells were fixed and erythrocytes were lysed using Invitrogen
Fix&Perm kit. Cells were washed with PBS/BSA 1% and analyzed
using a BD
TM LSR II flow cytometer. Proper isotype controls
were included for TLR antibodies. The percentage of TLR
expressing cells and the level of expression per cell was calculated:
delta (D) MFI=MFITLR2MFIisotype. Cut-off values for mTLR4
expression by HC monocytes were calculated: mean
DMFITLR4+2?SD and mean % TLR4
+ cells+2?SD.
For intracellular TLR9 staining, cells were labeled with
membrane markers, fixed and permeabilized (Invitrogen Fix&
Perm kit), and incubated with anti-TLR9 antibody or an isotype
control. Intracellular TLR9 expression is presented as delta-mean
fluorescence intensity: DMFI=MFITLR92MFIisotype. Flowcyto-
metry data was analyzed using Winlist 6.0 (Verity Software
House).
Effect of ANCA on TLR expression by monocytes and
granulocytes
To study whether stimulation with anti-PR3 antibodies or
PR3-ANCA influences TLR2 or TLR4 expression, cells from
whole blood were stimulated in vitro, and TLR expression by
monocytes and granulocytes was analyzed. Briefly, heparinized
blood from healthy volunteers was diluted 1:1 in RPMI
(Cambrex Bio Science), and stimulated for 5 hours in the
presence of mouse-anti-human PR3 monoclonal antibody
(5 mg/ml) or isolated PR3-ANCA IgG (200 mg/ml). An irrelevant
monoclonal antibody of the same isotype and healthy control IgG
were used as controls. TNF-a served as a positive control. After
stimulation, cells were washed, and stained with FITC-labeled
monoclonal antibodies against TLR2 (eBioscience), and APC-
labeled monoclonal antibodies against TLR4 (eBioscience). Cells
were analyzed using FACSCalibur
TM (BD). Specific monocyte
and granulocyte populations were identified by forward-sideward
scatter profiles, and TLR2 and TLR4 expression was analyzed on
these subsets.
Table 1. Patient characteristics.
Total number 38
PR3-ANCA/MPO-ANCA 22/16
Active/remission 6/32
Age (mean 6 sd) 60.6613.8
Diagnosis
Wegener’s granulomatosis 26
Microscopic polyangiitis 6
Necrotizing Crescentic Glomerulonephritis 6
ANCA titer (median, range)
PR3-ANCA pts (c-ANCA) 1:80 (1:20–1:640)
MPO-ANCA pts (p-ANCA) 1:80 (1:20–1:320)
Nasal carriage of S. aureus (+/2) 13/25
Receiving / not receiving treatment 25/13
ANCA: Antineutrophil cytoplasmic antibodies.
PR3: Proteinase-3.
MPO: Myeloperoxidase.
doi:10.1371/journal.pone.0024315.t001
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Production of cytokines, and the expression of the leukocyte
activation marker CD25 by peripheral blood leukocytes from
AAV patients (n=15), and HC (n=9), were studied ex vivo. Whole
blood (500 ml) was diluted 1:1 in RPMI (Cambrex Bio Science),
and stimulated for 24 h in the presence of 10 mg/ml Lipoteichoic
Acid (Invivogen), 10 mg/ml Lipopolysachharide (Ultra pure,
Invivogen), and 10 mg/ml CpG ODN 2006 (Hycult Biotechnol-
ogy). After 24 h, expression of the activation marker CD25 by B-
lymphocytes, monocytes, and granulocytes was analyzed using
flowcytometry. Release of cytokines IL-6, IL-8, IL-10, and TNF-a
into the supernatant was measured by ELISA.
Measurement of ANCA titers
Serum ANCA titers were determined by indirect immunoflu-
orescence on ethanol-fixed human granulocytes according to
standard procedures, as previously described [35]. Titers were
considered positive if equal to, or higher than 1:20.
Nasal carriage of Staphylococcus aureus
Patients with ANCA-associated vasculitis who visit our outpa-
tient clinic are routinely tested for nasal carriage of S. aureus as
described before [5]. Briefly, nasal swabs were inoculated on 5%
sheep-blood and salt mannitol agar and cultured overnight. S.
aureus was identified by coagulase and DNase positivity.
Figure 1. Gating strategies to distinguish between leukocyte populations. FSc-SSc profile was used to distinguish lymphocytes, monocytes
and granulocytes (A). Within the lymphocyte population, B lymphocytes, T lymphocytes, and NK cells were identified using membrane markers CD19,
CD3 and CD16/CD56, respectively (B, D). Monocytes were either CD14
+/CD16
low or CD14
low/CD16
+ (C).
doi:10.1371/journal.pone.0024315.g001
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Statistical analyses were performed using Graphpad Prism 5.0.
The non-parametric Mann-Whitney U test was used to analyze
percentages of TLR
+ NK cells, and to compare TLR expression by
monocytes, in AAV patients and HC. To compare TLR expression
by monocytes in S. aureus
+ or S. aureus
2 AAV patients, either the
non-parametric Mann-Whitney U test, or the unpaired t test were
used. To compare CD25 expression, and the release of cytokines
between AAV patient and HC cultures, either the non-parametric
Mann-Whitney U test, or the unpaired t test were used.
P values lower than 0.05 (2-tailed) were considered significant.
Results
Leukocyte Toll-like receptor expression
Leukocyte populations were distinguished according to light
scatter profile and the expression of surface markers CD3, CD14,
CD16, CD19, CD27, and CD56 (figure 1). All TLR expression
data are summarized in table 2 and, additionally, part of the data
are shown in graphs.
Membrane TLR (mTLR) expression on B- and T-lymphocytes
did not differ between AAV patients and healthy controls (HC)
(table 2). Intracellular expression of TLR9 (iTLR9) in the total B
lymphocyte population was significantly lower in AAV patients,
but did not differ between AAV patients and HC when B
lymphocytes were subdivided into CD27
2 (naı ¨ve) and CD27
+
(memory) subsets (table 2). In T-lymphocytes, iTLR9 levels were
significantly decreased in AAV patients (P=0.006).
In both AAV patients and HC we detected low mTLR
expression by NK cells. In AAV patients, proportions of mTLR2
+,
mTLR4
+, and mTLR9
+ expressing NK cells were increased
compared to HC (p=0.005, p=0.03, and p=0.05, respectively,
figure 2). iTLR9 expression was significantly lower in AAV patient
NK cells (p=0.008). The percentage of NK cells – within the total
Table 2. Toll-like receptor expression by peripheral blood leukocytes.
AAV patients (n=38) Healthy controls (n=20) P value
B lymphocytes
mTLR2 (% pos cells) 0,51 (0–3.87) 0.84 (0–14.9) 0.26
mTLR4 (% pos. cells) 2.75 (0–13.8) 3.19 (0–11.62) 0.73
mTLR9 (% pos. cells) 2.67 (0.75–13.9) 3.82 (1.05–64.8) 0.27
iTLR9 (all B cells, DMFI) 10.26 (4.67–73.11) 16.07 (6.88–31.05) 0.009
iTLR9 (CD27
2 B cells, DMFI) 11.564.4 13.264.1 0.30
iTLR9 (CD27
+ B cells, DMFI) 20.066.8 22.165.6 0.37
T lymphocytes
mTLR2 (% pos. cells) 0.01 (0–0.26) 0.03 (0–0.46) 0.34
mTLR4 (% pos. cells) 0.17 (0–6.6) 0.40 (0–22.7) 0.14
mTLR9 (% pos. cells) 0.23 (0–1.8) 0.36 (0–1.69) 0.33
iTLR9 (DMFI) 13.03 (5.6–66.1) 18.1 (11.4–47.2) 0.006
NK cells
mTLR2 (% pos. cells) 0.48 (0–1.46) 0.20 (0–1.36) 0.005
mTLR4 (% pos. cells) 0.47 (0–1.84) 0.27 (0–0.77) 0.03
mTLR9 (% pos. cells) 0.43 (0–3.19) 0.14 (0–3.59) 0.05
iTLR9 (DMFI) 10.0 (6.1–68.7) 16.4 (6.9–35.0) 0.008
Monocytes
mTLR2 (% pos. cells) 96.6 (58.1–99.4) 95.5 (66.0–99.3) 0.38
mTLR2 (DMFI) 29.7 (12.7–93.6) 19.9 (8.7–69.0) 0.03
mTLR4 (% pos. cells) 1.72 (0.1–65.9) 1.65 (0.1–6.88) 0.99
mTLR4 (DMFI) 5.82 (0–27.5) 4.19 (0–11.3) 0.10
mTLR9 (% pos. cells) 11.58 (0–77.6) 10.9 (0–51.0) 0.72
mTLR9 (DMFI) 6.66 (0–61.2) 5.13 (0.1–21.8) 0.87
iTLR9 (DMFI) 27.6 (7.8–160) 30.4 (16.0–53.4) 0.58
Granulocytes
mTLR2 (% pos. cells) 5.6 (0–62.3) 6.24 (0–61.6) 0.95
mTLR2 (DMFI) 1.9 (0–15.3) 1.6 (0–16.4) 0.25
mTLR4 (% pos. cells) 0.31 (0–4.6) 0.36 (0–18.6) 0.87
mTLR4 (DMFI) 1.10 (0–9.0) 1.14 (0–13.5) 0.62
mTLR9 (% pos. cells) 0.10 (0–68.6) 0.20 (0–66.1) 0.45
mTLR9 (DMFI) 1.62 (0–170) 1.3 (0–28.4) 0.66
iTLR9 (DMFI) 12.7 (1.73–57.3) 17.1 (0–54.5) 0.22
MFI: Mean fluorescence intensity.
doi:10.1371/journal.pone.0024315.t002
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patients and HC, and a comparable ratio between CD56
bright
and CD56
dim NK cells was observed in AAV patients and HC
(data not shown).
mTLR2 was highly expressed by monocytes from both AAV
patients and HC. Percentages of mTLR2
+ (figure 3A) monocytes
were comparable, but mTLR2 levels were increased on AAV
patient monocytes (p=0.03, figure 3B). Expression of both
mTLR4 and mTLR9 did not differ significantly between AAV
patient and HC monocytes, although 7 AAV patients had an
increased proportion of mTLR4
+ monocytes and increased level of
mTLR4, compared to HC (figure 3D,E). iTLR9 levels were
comparable in AAV patient and HC monocytes.
Expression of mTLRs and iTLR9 did not differ between AAV
patient and HC granulocytes (table 2).
No differential TLR expression was observed in patients with
active disease (n=6), compared to patients in remission. No
relation was found between TLR expression and serum ANCA
titers.
Effect of monoclonal anti-PR3 antibody and PR3-ANCA
IgG priming on mTLR expression by monocytes and
granulocytes
To study whether priming with anti-PR3 monoclonal antibodies
or PR3-ANCA IgG influences TLR expression, we studied the
expression of membrane TLR2 and TLR4 by monocytes and
granulocytes after in vitro stimulation with monoclonal anti-PR3
antibodies, or PR3-ANCA IgG. We did not observe an increase in
mTLR expression after stimulation, whereas TNF-a induced
increased TLR expression (data not shown).
Carriage of Staphylococcus aureus and TLR expression
To study whether nasal carriage of Staphylococcus aureus
influences the expression of TLRs by circulating leukocytes, the
expression of TLRs was compared between AAV patients who
were nasal carriers of S. aureus at the time of blood sampling
(n=13), and non-carriers (n=25). Expression of TLRs by B
lymphocytes, T lymphocytes, NK cells and granulocytes was
comparable in nasal carriers and non-carriers (data not shown).
Monocytes from nasal carriers of S. aureus had increased iTLR9
levels compared to non-carriers (p=0.03, figure 4), and within the
7 patients with a high proportion of TLR4 expressing monocytes,
5 were nasal carriers of S. aureus (p=0.03, chi-square).
Whole blood stimulation with LTA, LPS, CpG
To study if TLR stimulation could trigger differential responses
in AAV patients and HC, cells in whole blood were stimulated
with specific TLR ligands. Leukocytes from patients and HC
showed a comparable pattern of CD25 expression after TLR
stimulation. B lymphocytes were specifically triggered by CpG,
whereas monocytes and granulocytes were most responsive to
TLR2 and TLR4 stimulation (figure 5). In line with these
observations we observed a comparable pattern of cytokine release
in response to TLR stimulation (figure 6). In the unstimulated
condition, AAV patients released more TNF-a than HC, but upon
LPS stimulation, AAV patients released significantly less TNF-a
(p=0.04). Interestingly, AAV patients tended to release more IL-
10 in response to LTA, although this did not reach statistical
significance (p=0.06).
Discussion
TLRs sense specific bacterial components, and bacterial
infections have been associated with AAV [3,9,36]. The expression
levels of TLRs on peripheral leukocytes and the functional
consequences of TLR activation have not been studied yet in
AAV. Our study is the first to characterize TLR expression by
circulating B lymphocytes, T lymphocytes, NK cells, monocytes,
and granulocytes from AAV patients. We observed increased
expression of membrane TLR2 (mTLR2) by monocytes, and, in a
subset of patients, increased mTLR4. Furthermore, patients had
increased proportions of TLR-expressing NK cells. Increased
TLR expression by monocytes was found in nasal carriers of
Staphylococcus aureus. Stimulation with neither anti-PR3 monoclonal
antibodies nor anti-PR3 IgG influenced TLR expression by
monocytes and granulocytes, and in vitro responses to TLR
stimulation did not differ significantly between AAV patients and
HC.
We observed increased expression of mTLR2 by monocytes in
patients with AAV. TLR2 senses components from the Gram-
positive bacterial cell wall such as peptidoglycan and lipoteichoic
acid [37]. Monocytes increase mTLR2 expression upon stimula-
tion by proinflammatory cytokines and TLR-ligands [12], and our
finding may well reflect increased activation of monocytes, as
reported previously in AAV [38,39]. It has been described that
proinflammatory monocytes (CD14
dimCD16
++) express higher
mTLR2 levels than CD14
+CD16
dim monocytes [40], and,
therefore, we studied whether AAV patients had higher propor-
tions of proinflammatory monocytes. However, proportions of
proinflammatory monocytes were comparable between AAV
patients and HC (data not shown), indicating increased mTLR2
expression by all monocytes. mTLR4 levels on patient monocytes
did not differ significantly from HC, but, interestingly, 7 AAV
patients had increased proportions of mTLR4
+ monocytes when
compared to HC. This apparent discrepancy between mTLR2
and mTLR4 expression by monocytes may be explained by
difference in expression kinetics of these TLRs. Indeed, previous
studies have shown that mTLR4 levels decrease relatively fast after
Figure 2. Expression of mTLR2, mTLR4, and mTLR9 by Natural
killer (NK) cells. Cells in whole blood were labeled with antibodies
against CD56, CD16, TLR2, TLR4, and TLR9. NK cells were gated
according to light scatter profile and the expression of CD56/CD16.
Proportions of mTLR2, mTLR4, and mTLR9 positive NK cells in HC and
AAV patients are shown. Within patients, closed circles depict TLR
expression in active patients (n=6). Proportions of mTLR2
+, mTLR4
+,
and mTLR9
+ NK cells were significantly increased in AAV patients
(p=0.005, p=0.03, and p=0.05, respectively). Proportions of mTLR
expressing NK cells did not differ between patients with active disease
or in remission.
doi:10.1371/journal.pone.0024315.g002
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longer period of time [12].
The increased proportion of TLR-expressing NK cells in AAV
patients is of interest. NK cells express mRNA for TLR1–10, and
produce TNF-a in response to several TLR ligands including
peptidoglycan, LPS and poly I:C [41]. The increased proportions
of mTLR expressing NK cells thus may reflect a pro-inflammatory
environment in AAV patients. Within the total NK cell
population, two NK cell subsets can be distinguished, based on
the expression level of CD56. CD56
bright NK cells can produce
cytokines such as interferon-c and tumor necrosis factor-a,
whereas CD56
dim NK cells have cytotoxic capactity [42]. We
analyzed whether NK cell numbers, or the CD56
bright/CD56
dim
ratio differed in AAV patients, but found these characteristics to be
comparable with HC (data not shown). NK cells play an important
role during bacterial and viral infection, and are critically required
during host defense against S. aureus infection in the lung [43].
However, we did not observe increased proportions of TLR
expressing NK-cells in nasal carriers of S. aureus.
Intracellular TLR9 (iTLR9) is involved in the recognition of
CpG motifs from bacterial DNA [44]. We observed decreased
iTLR9 in B lymphocytes, T lymphocytes, and NK cells from AAV
patients, whereas iTLR9 levels in monocytes and granulocytes
were comparable in patients and HC. Increased iTLR9 expression
has been shown in memory B lymphocytes and, therefore, we
additionally analyzed iTLR9 levels in naı ¨ve (CD27
2) and memory
(CD27
+) B lymphocytes. In accordance with previous reports we
found higher iTLR9 levels in memory B lymphocytes, compared
to naı ¨ve B lymphocytes [45]. Decreased iTLR9 levels in patients
are in line with lower proportions of memory B lymphocytes in
AAV patients. Whether decreased iTLR9 levels in T lymphocytes
and NK cells reflect differential T lymphocyte and NK cell subsets
in patients as well, could not be determined with the antibody-
panel that was used in this study. T lymphocytes have been studied
extensively in AAV, and are shifted towards an effector memory
T-cell phenotype [46] but whether these cells express lower levels
of iTLR9 is not known.
As mentioned earlier, patients with Wegener’s granulomatosis
are often chronic nasal carriers of S. aureus and carriage is
associated with an increased risk for relapses. TLRs are important
orchestrators of the immune system during pathogen invasion
[20,21], and altered TLR expression has been reported during
bacterial infections [47,48]. Therefore, we compared TLR
expression in nasal carriers of S. aureus and non-carriers. We
observed increased iTLR9 levels in monocytes from S. aureus
carriers, and interestingly, 5 out of 7 patients with increased
proportions of monocytes expressing mTLR4 were S. aureus
+ at the
moment of inclusion. These observations suggest increased
activation of monocytes in nasal carriers of S. aureus and it will
be important to follow-up on these patients and monitor the
development of relapses.
Key players in AAV are the ANCA autoantibodies that are
capable to activate monocytes and granulocytes [49,50]. Uehara
et al. found highly increased expression of TLR2, TLR3, TLR4,
TLR7, and TLR9 by peripheral blood mononuclear cells after
stimulation with mouse anti-human PR3 monoclonal antibody
[30]. This suggests that ANCA may increase the sensitivity to TLR
ligands by influencing TLR expression in AAV. However,
Figure 3. Expression of mTLR2 and mTLR4 by monocytes. Cells in whole blood were stained with antibodies against CD14, CD16, TLR2, and
TLR4. Monocytes were gated according to light scatter profile and the expression of CD14/CD16. Representative histogram plots of mTLR2 and
mTLR4 expression are shown in figures C and F, respectively. The proportions of mTLR2
+ (A) and mTLR4
+ (D) monocytes did not differ between AAV
patients and HC. However, 7 AAV patients had an increased proportion of mTLR4
+ monocytes, compared to HC (dotted line: cut-off mTLR4
+ cells,
calculated from HC). Expression levels per cell are shown in fig B (mTLR2), and E (mTLR4). mTLR2 levels were higher on AAV patient monocytes,
compared to HC (p=0.03), whereas mTLR4 levels did not differ significantly when comparing groups. In line with increased proportions of mTLR4
+
monocytes, in part of the patients increased levels of mTLR4 were observed (dotted line: cut-off mTLR4 DMFI, calculated from HC) Within AAV
patients, active patients (n=6) are depicted with closed circles. Expression of mTLR2 and mTLR4 did not differ significantly between patients with
active or quiescent disease.
doi:10.1371/journal.pone.0024315.g003
Figure 4. Toll-like receptor expression by monocytes from AAV patients who were nasal carriers of S. aureus (n=13, white bars) and
non-carriers (n=25, gray bars). Both the proportions of mTLR
+ monocytes (left y-axis), as well as the level of mTLR expression (right y-axis) did
not differ significantly between monocytes from nasal carriers and non-carriers. Intracellular levels of TLR9 (iTLR9) were increased in monocytes from
patients who were nasal carriers of S. aureus.
doi:10.1371/journal.pone.0024315.g004
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priming on monocyte TLR expression [31]. In line with these
results we found no effect of priming with anti-PR3 monoclonal
antibodies or isolated PR3-ANCA IgG on TLR expression by
monocytes and granulocytes either. In addition, no relation
between serum ANCA titers and leukocyte TLR expression was
observed.
Additional to the analysis of TLR expression, we compared ex vivo
responses to TLR ligands between AAV patients and HC. Several
studies have reported increased proinflammatory responses to TLR
ligands in various diseases [47,51,52]. However, although minor
differences were observed, responsiveness to TLR ligands in AAV
patients and healthy controls was largely comparable.
In this study, we observed increased expression of mTLR2, and
partly mTLR4, by circulating monocytes from AAV patients.
Furthermore, increased proportions of mTLR2
+, mTLR4
+, and
mTLR9
+ NK cells were found in AAV patients. This may reflect
increased activation of these cells in AAV. No relation was found
between ANCA titers and TLR expression, and in vitro stimulation
with monoclonal anti-PR3 antibody or isolated PR3-ANCA IgG,
did not alter leukocyte TLR expression either. Interestingly, we
observed increased TLR expression by monocytes from nasal
carriers of S. aureus, indicating increased activation of these cells.
These findings warrant further investigation of TLRs in relation
to AAV. Local expression and function of TLRs at sites of
inflammation will need to be investigated. Functional studies
should point out whether TLRs play a role in the response to
bacterial triggers and can contribute to disease activation and
relapses in AAV.
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Figure 5. Expression of the activation marker CD25 by leukocyte subsets was analyzed after stimulation with TLR ligands. Diluted
whole blood was left unstimulated or treated with Lipoteichoic acid (TLR2 ligand), Lipopolysaccharide (TLR4 ligand), or CpG-ODN (TLR9 ligand). After
24 h, expression of CD25 by different leukocyte subsets was analyzed by flowcytometry (A). Leukocyte subsets were distinguished according to light
scatter profile (lymphocytes, monocytes, granulocytes) and the expression of CD19 (B lymphocytes). In both AAV patients (open circles) and HC (filled
circles), increased CD25 expression was observed by monocytes and granulocytes, in response to TLR2 and TLR4 stimulation. Particularly B
lymphocytes were stimulated by CpG-ODN. Significantly increased CD25 expression is depicted with * (HC) and # (AAV patients).
doi:10.1371/journal.pone.0024315.g005
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